Last reviewed · How we verify
Diamazol (etoxazene)
Diamazol (generic name: etoxazene) is a drug developed by Squibb. It is currently FDA-approved for Urinary tract pain.
At a glance
| Generic name | etoxazene |
|---|---|
| Sponsor | Squibb |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Urinary tract pain
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diamazol CI brief — competitive landscape report
- Diamazol updates RSS · CI watch RSS
- Squibb portfolio CI
Frequently asked questions about Diamazol
What is Diamazol?
Diamazol (etoxazene) is a pharmaceutical drug developed by Squibb, indicated for Urinary tract pain.
What is Diamazol used for?
Diamazol is indicated for Urinary tract pain.
Who makes Diamazol?
Diamazol is developed and marketed by Squibb (see full Squibb pipeline at /company/squibb).
What is the generic name of Diamazol?
etoxazene is the generic (nonproprietary) name of Diamazol.
What development phase is Diamazol in?
Diamazol is FDA-approved (marketed).
Related
- Manufacturer: Squibb — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Urinary tract pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing